Review article: Integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis

S. Danese, C. A. Siegel, L. Peyrin-Biroulet

Research output: Contribution to journalArticle

Abstract

Background 5-Aminosalicylates (5-ASA) are first-line treatment for mild-moderately active ulcerative colitis (UC). When 5-ASAs fail, systemic corticosteroids have been the standard next step. Due to the significant side effect profile of systemic corticosteroids, alternative options in the treatment algorithm after 5-ASA failures are needed. Budesonide-Multi-Matrix System (MMX) is a novel oral formulation of budesonide that uses colonic release MMX technology to extend release of the drug to the colon. Now that budesonide-MMX has been approved for use in some countries, and pending in others we need to understand its position in the treatment algorithm for UC. Aim To review the available literature for budesonide-MMX and incorporate it into the treatment algorithm for mild-moderate UC. Methods The available efficacy and safety literature regarding budesonide-MMX was reviewed, and compared to 5-ASAs and systemic corticosteroids. Results In two large studies referred to as CORE (Colonic Release Budesonide trial), budesonide-MMX 9 mg daily was significantly more effective in achieving a combined end point of clinical and endoscopic remission than placebo in patients with mild-moderately active UC. Safety data are reassuring, with no clinically relevant differences between budesonide-MMX and placebo, including steroid-related side effects. Conclusions Budesonide-MMX 9 mg daily is an effective and safe treatment for induction in patients with mild-moderately active UC. At the current time, it should be considered in patients after 5-ASA failure and before systemic corticosteroids. Data are still needed to understand its role and dose beyond 8 weeks, and if it should be considered first line before 5-ASAs.

Original languageEnglish
Pages (from-to)1095-1103
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume39
Issue number10
DOIs
Publication statusPublished - 2014

Fingerprint

Budesonide
Ulcerative Colitis
Mesalamine
Adrenal Cortex Hormones
Therapeutics
Placebos
Safety
Colon
Steroids
Technology

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Review article : Integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. / Danese, S.; Siegel, C. A.; Peyrin-Biroulet, L.

In: Alimentary Pharmacology and Therapeutics, Vol. 39, No. 10, 2014, p. 1095-1103.

Research output: Contribution to journalArticle

@article{ffe1971c1344465d8df8a479e4ac945e,
title = "Review article: Integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis",
abstract = "Background 5-Aminosalicylates (5-ASA) are first-line treatment for mild-moderately active ulcerative colitis (UC). When 5-ASAs fail, systemic corticosteroids have been the standard next step. Due to the significant side effect profile of systemic corticosteroids, alternative options in the treatment algorithm after 5-ASA failures are needed. Budesonide-Multi-Matrix System (MMX) is a novel oral formulation of budesonide that uses colonic release MMX technology to extend release of the drug to the colon. Now that budesonide-MMX has been approved for use in some countries, and pending in others we need to understand its position in the treatment algorithm for UC. Aim To review the available literature for budesonide-MMX and incorporate it into the treatment algorithm for mild-moderate UC. Methods The available efficacy and safety literature regarding budesonide-MMX was reviewed, and compared to 5-ASAs and systemic corticosteroids. Results In two large studies referred to as CORE (Colonic Release Budesonide trial), budesonide-MMX 9 mg daily was significantly more effective in achieving a combined end point of clinical and endoscopic remission than placebo in patients with mild-moderately active UC. Safety data are reassuring, with no clinically relevant differences between budesonide-MMX and placebo, including steroid-related side effects. Conclusions Budesonide-MMX 9 mg daily is an effective and safe treatment for induction in patients with mild-moderately active UC. At the current time, it should be considered in patients after 5-ASA failure and before systemic corticosteroids. Data are still needed to understand its role and dose beyond 8 weeks, and if it should be considered first line before 5-ASAs.",
author = "S. Danese and Siegel, {C. A.} and L. Peyrin-Biroulet",
year = "2014",
doi = "10.1111/apt.12712",
language = "English",
volume = "39",
pages = "1095--1103",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "10",

}

TY - JOUR

T1 - Review article

T2 - Integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis

AU - Danese, S.

AU - Siegel, C. A.

AU - Peyrin-Biroulet, L.

PY - 2014

Y1 - 2014

N2 - Background 5-Aminosalicylates (5-ASA) are first-line treatment for mild-moderately active ulcerative colitis (UC). When 5-ASAs fail, systemic corticosteroids have been the standard next step. Due to the significant side effect profile of systemic corticosteroids, alternative options in the treatment algorithm after 5-ASA failures are needed. Budesonide-Multi-Matrix System (MMX) is a novel oral formulation of budesonide that uses colonic release MMX technology to extend release of the drug to the colon. Now that budesonide-MMX has been approved for use in some countries, and pending in others we need to understand its position in the treatment algorithm for UC. Aim To review the available literature for budesonide-MMX and incorporate it into the treatment algorithm for mild-moderate UC. Methods The available efficacy and safety literature regarding budesonide-MMX was reviewed, and compared to 5-ASAs and systemic corticosteroids. Results In two large studies referred to as CORE (Colonic Release Budesonide trial), budesonide-MMX 9 mg daily was significantly more effective in achieving a combined end point of clinical and endoscopic remission than placebo in patients with mild-moderately active UC. Safety data are reassuring, with no clinically relevant differences between budesonide-MMX and placebo, including steroid-related side effects. Conclusions Budesonide-MMX 9 mg daily is an effective and safe treatment for induction in patients with mild-moderately active UC. At the current time, it should be considered in patients after 5-ASA failure and before systemic corticosteroids. Data are still needed to understand its role and dose beyond 8 weeks, and if it should be considered first line before 5-ASAs.

AB - Background 5-Aminosalicylates (5-ASA) are first-line treatment for mild-moderately active ulcerative colitis (UC). When 5-ASAs fail, systemic corticosteroids have been the standard next step. Due to the significant side effect profile of systemic corticosteroids, alternative options in the treatment algorithm after 5-ASA failures are needed. Budesonide-Multi-Matrix System (MMX) is a novel oral formulation of budesonide that uses colonic release MMX technology to extend release of the drug to the colon. Now that budesonide-MMX has been approved for use in some countries, and pending in others we need to understand its position in the treatment algorithm for UC. Aim To review the available literature for budesonide-MMX and incorporate it into the treatment algorithm for mild-moderate UC. Methods The available efficacy and safety literature regarding budesonide-MMX was reviewed, and compared to 5-ASAs and systemic corticosteroids. Results In two large studies referred to as CORE (Colonic Release Budesonide trial), budesonide-MMX 9 mg daily was significantly more effective in achieving a combined end point of clinical and endoscopic remission than placebo in patients with mild-moderately active UC. Safety data are reassuring, with no clinically relevant differences between budesonide-MMX and placebo, including steroid-related side effects. Conclusions Budesonide-MMX 9 mg daily is an effective and safe treatment for induction in patients with mild-moderately active UC. At the current time, it should be considered in patients after 5-ASA failure and before systemic corticosteroids. Data are still needed to understand its role and dose beyond 8 weeks, and if it should be considered first line before 5-ASAs.

UR - http://www.scopus.com/inward/record.url?scp=84898853766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898853766&partnerID=8YFLogxK

U2 - 10.1111/apt.12712

DO - 10.1111/apt.12712

M3 - Article

C2 - 24641622

AN - SCOPUS:84898853766

VL - 39

SP - 1095

EP - 1103

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 10

ER -